Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.70 | 71.20 | 0.81% |
| CAC 40 | 8,238.04 | 76.21 | 0.93% |
| DAX 40 | 24,246.81 | 51.50 | 0.21% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,356.51 | 101.70 | 0.99% |
| HKSE | 24,249.29 | 158.67 | -0.65% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 64,217.27 | 38.00 | 0.06% |
| NZX 50 Index | 13,202.16 | 51.49 | -0.39% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,633.20 | 69.70 | 0.81% |
| SSE Composite Index | 3,987.01 | 6.21 | -0.16% |